Skip to content

A single-blind, randomized, controlled clinical study of flash stimulation therapy in Parkinson's disease

A single-blind, randomized, controlled clinical study of flash stimulation therapy in Parkinson's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097653
Enrollment
Unknown
Registered
2025-02-24
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

100Hz flash stimulation group:100hzFlash stimulation therapy
40Hz flash stimulation group:40hzFlash stimulation therapy

Sponsors

The second affiliated hospital of Zhejiang University school of medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. PD patients who meet the diagnostic criteria of the International Movement Disorders Association (MDS), between the ages of 50 and 70 years, the course of disease <=5 years, and the Hoehn & Yahr stage <=3; 2. Anti-PD drugs were taken regularly for at least one month before screening, and symptoms were stable; 3. The fixed bedtime in the past month is between 9:00 p.m. and 1:00 a.m., and the total sleep time is =6 hours; 4. Have the ability to understand and voluntarily sign informed consent; 5. Have good compliance and are willing to complete all follow-up required by this program.

Exclusion criteria

Exclusion criteria: 1. Secondary insomnia: including sleep disorders (restless leg syndrome, periodic limb movement disorder, sleep-related breathing disorders, etc.), physical diseases, mental disorders, psychoactive substance abuse; 2. suffering from photosensitive dermatitis, epilepsy and other diseases that are not suitable for flash stimulation; 3. Alcohol, coffee, or drug abusers in the past 6 months; 4. Mental illness: such as anxiety, depression, schizophrenia and post-traumatic stress disorder caused by insomnia; 5. Used drugs or health products that regulate sleep function or affect sleep within 14 days before enrollment or less than 5 drug half-lives; 6. Taking drugs that may impair cognitive ability, such as anticholinergic drugs, memory enhancing drugs, etc., within 7 days before enrollment; 7. the subject is unable to complete the test or follow-up; 8. suffering from other neurodegenerative diseases; 9. There are endoplants in the body that cannot be examined by MRI; 10. Inability to lie flat; 11. Other situations in which the researcher considers it inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
Cerebral lymphoid parameters;

Secondary

MeasureTime frame
motor symptoms;EEG parameters;

Countries

China

Contacts

Public ContactZhang Baorong

The second affiliated hospital of Zhejiang University school of medicine

brzhang@zju.edu.cn+86 571 87784752

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026